Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

Novo sells semaglutide as Ozempic, Rybelsus and Wegovy. The CMS will treat the different forms as a single product in price ...

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS ...

Semaglutide (Ozempic) is 1 of 15 medications that will be included in yearly price negotiations between Medicare and ...

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

Announcement of the 15 medicines chosen for the second round of negotiations was one of the Biden administration’s final ...

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular semaglutide medicines as one of the 15 additional drugs covered under ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...